Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Technology Scientific & Technical Instruments
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Anytime V4.0 and Sales 2025! Just Imagine what the FDA V4.0!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Post by jopatcloon Jan 01, 2025 1:46pm
125 Views
Post# 36383439

Anytime V4.0 and Sales 2025! Just Imagine what the FDA V4.0!

Anytime V4.0 and Sales 2025! Just Imagine what the FDA V4.0!Happy Great year 2025 & Stocks go up and down, and that's a fact. Anytime V4.0 and Sales 2025! Just Imagine what the FDA V4.0 approval now every day brings us closer to dear friends... FDA news announcement will do. Now with Mayo Clinic & The BEST automation and analysis of the PLANET GEN3EHO Remember Bashers game too May 6-2024 close 0.29 and top 0.30 This week in 2024 Hugh post ''We are nearing the completion of updated business and operational plans and will share elements of these in early 2025. we were able to accomplish key objectives in 2024 that include: · completing and releasing VMS+ v3.2 which features an important hardware update that users report has improved reliability and accelerated workflow · completing VMS+ v4 which has now received the CE mark in Europe, a Medical Device License in Canada, and has been submitted for 510(k) clearance in the United States. · strengthening our collaboration with ASCEND Cardiovascular in the U.S. · sales of systems to two of the leading cardiology centers in the U.S. · implementing CRM and project management platforms · continuing to build our commercial team '' Go Ventripoint 2025#vpt,
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities